Glycine transporter-1: a new potential therapeutic target for schizophrenia
- PMID:21355838
- DOI: 10.2174/138161211795049598
Glycine transporter-1: a new potential therapeutic target for schizophrenia
Abstract
The hypofunction hypothesis of glutamatergic neurotransmission via N-methyl-D-aspartate (NMDA) receptors in the pathophysiology of schizophrenia suggests that increasing NMDA receptor function via pharmacological manipulation could provide a new therapeutic strategy for schizophrenia. The glycine modulatory site on NMDA receptor complex is the one of the most attractive therapeutic targets for schizophrenia. One means of enhancing NMDA receptor neurotransmission is to increase the availability of the obligatory co-agonist glycine at modulatory site on the NMDA receptors through the inhibition of glycine transporter-1 (GlyT-1) on glial cells. Some clinical studies have demonstrated that the GlyT-1 inhibitor sarcosine (N-methylglycine) shows antipsychotic activity in patients with schizophrenia. Currently, a number of pharmaceutical companies have been developing novel and selective GlyT-1 inhibitors for the treatment of schizophrenia. A recent double blind phase II study demonstrated that the novel GlyT-1 inhibitor RG1678 has a robust and clinically meaningful effect in patients with schizophrenia. In this article, the author reviews the recent findings on the GlyT-1 as a potential therapeutic target of schizophrenia.
Similar articles
- Glycine transport inhibitors for the treatment of schizophrenia.Hashimoto K.Hashimoto K.Open Med Chem J. 2010 May 27;4:10-9. doi: 10.2174/1874104501004010010.Open Med Chem J. 2010.PMID:21253021Free PMC article.
- Glutamate-based therapeutic approaches: inhibitors of glycine transport.Lechner SM.Lechner SM.Curr Opin Pharmacol. 2006 Feb;6(1):75-81. doi: 10.1016/j.coph.2005.11.002. Epub 2005 Dec 22.Curr Opin Pharmacol. 2006.PMID:16376148Review.
- Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms.Harsing LG Jr, Timar J, Szabo G, Udvari S, Nagy KM, Marko B, Zsilla G, Czompa A, Tapolcsanyi P, Kocsis A, Matyus P.Harsing LG Jr, et al.Curr Pharm Des. 2015;21(17):2291-303. doi: 10.2174/1381612821666150109125623.Curr Pharm Des. 2015.PMID:25578890
- Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.Kawaura K, Koike H, Kinoshita K, Kambe D, Kaku A, Karasawa J, Chaki S, Hikichi H.Kawaura K, et al.Behav Brain Res. 2015 Feb 1;278:186-92. doi: 10.1016/j.bbr.2014.09.046. Epub 2014 Oct 6.Behav Brain Res. 2015.PMID:25300471
- Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG.Lindsley CW, et al.Curr Top Med Chem. 2006;6(8):771-85. doi: 10.2174/156802606777057599.Curr Top Med Chem. 2006.PMID:16719816Review.
Cited by
- The Cellular Dysfunction of the Brain-Blood Barrier from Endothelial Cells to Astrocytes: The Pathway towards Neurotransmitter Impairment in Schizophrenia.Stanca S, Rossetti M, Bokulic Panichi L, Bongioanni P.Stanca S, et al.Int J Mol Sci. 2024 Jan 19;25(2):1250. doi: 10.3390/ijms25021250.Int J Mol Sci. 2024.PMID:38279249Free PMC article.Review.
- Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.Hashimoto K, Malchow B, Falkai P, Schmitt A.Hashimoto K, et al.Eur Arch Psychiatry Clin Neurosci. 2013 Aug;263(5):367-77. doi: 10.1007/s00406-013-0399-y. Epub 2013 Mar 1.Eur Arch Psychiatry Clin Neurosci. 2013.PMID:23455590Review.
- Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.Monaghan DT, Irvine MW, Costa BM, Fang G, Jane DE.Monaghan DT, et al.Neurochem Int. 2012 Sep;61(4):581-92. doi: 10.1016/j.neuint.2012.01.004. Epub 2012 Jan 17.Neurochem Int. 2012.PMID:22269804Free PMC article.Review.
- Investigation of sedative and hypnotic effects of Amygdalus communis L. extract: behavioral assessments and EEG studies on rat.Abdollahnejad F, Mosaddegh M, Kamalinejad M, Mirnajafi-Zadeh J, Najafi F, Faizi M.Abdollahnejad F, et al.J Nat Med. 2016 Apr;70(2):190-7. doi: 10.1007/s11418-015-0958-9. Epub 2015 Dec 28.J Nat Med. 2016.PMID:26711831
- Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study.Camporesi S, Xin L, Golay P, Eap CB, Cleusix M, Cuenod M, Fournier M, Hashimoto K, Jenni R, Ramain J, Restellini R, Solida A, Conus P, Do KQ, Khadimallah I.Camporesi S, et al.Mol Psychiatry. 2024 Nov;29(11):3669-3679. doi: 10.1038/s41380-024-02631-4. Epub 2024 Jun 7.Mol Psychiatry. 2024.PMID:38849515Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical